AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: Trebor Banstetter
Aug. 1--FORT WORTH, Texas--Fueled by strong sales of its new glaucoma drug, eye-care giant Alcon saw its profit leap 58 percent during the second quarter.
The earnings report was the second to be posted by the company, which had its initial public offering in March. Alcon executives said sales grew 9 percent to $809 million during the quarter, compared with $746 million last year.
Profit jumped to $163 million for the quarter, compared with $103 million last year. The profit, which was 53 cents per share, exceeded Wall Street's expectations of about 43 cents per share.
Alcon Chief Executive Tim Sear didn't dabble with modesty when announcing the results.
"Alcon had a truly outstanding second quarter," he told analysts in a conference call Wednesday.
Alcon, the world's largest eye-care company, develops and manufactures optical surgery equipment, prescription eye-care drugs and contact lens solutions. About 75 percent of the Fort Worth-based company's stock is owned by Nestle S.A. of Vevey, Switzerland.